Search Images Maps Play Gmail Drive Calendar Translate More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2005026343 A1
Publication typeApplication
Application numberPCT/JP2004/013043
Publication date24 Mar 2005
Filing date8 Sep 2004
Priority date9 Sep 2003
Also published asDE602004032248D1, EP1674566A1, EP1674566A4, EP1674566B1, US7785596, US20070098701
Publication numberPCT/2004/13043, PCT/JP/2004/013043, PCT/JP/2004/13043, PCT/JP/4/013043, PCT/JP/4/13043, PCT/JP2004/013043, PCT/JP2004/13043, PCT/JP2004013043, PCT/JP200413043, PCT/JP4/013043, PCT/JP4/13043, PCT/JP4013043, PCT/JP413043, WO 2005/026343 A1, WO 2005026343 A1, WO 2005026343A1, WO-A1-2005026343, WO2005/026343A1, WO2005026343 A1, WO2005026343A1
InventorsHideyuki Okano, James Hirotaka Okano, Masanori Sakaguchi, Hidehiro Mizusawa, Satoru Ishibashi
ApplicantKeio University
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Method of promoting subsistence and/or proliferation of neural stem cell and promoting extension of neurite, promoter therefor, pharmaceutical composition containing neural stem cell, method of assay and method of screening
WO 2005026343 A1
Abstract
[PROBLEMS] To provide a method of promoting the subsistence and/or proliferation of neural stem cells; a pharmaceutical composition containing neural stem cells produced by the method; and a method of assaying and method of screening a factor capable of promoting the subsistence and/or proliferation of neural stem cells. [MEANS FOR SOLVING PROBLEMS] Excess expression of galectin-1 is effected in neural stem cells, or neural stem cells are cultured in a culture solution containing galectin-1. The pharmaceutical composition comprising the thus produced neural stem cells wherein excess expression of galectin-1 is effected and the pharmaceutical composition comprising galectin-1 ameliorate high-order functions having been disordered by intracerebral ischemia. There is further provided a method of assay, comprising seeding neural stem cells at a clonal concentration and determining whether or not the seeded neural stem cells can proliferate in an assay culture medium as an assay subject to thereby identify whether or not this factor promotes the subsistence and/or proliferation of neural stem cells. With the use of this assay method, the factor capable of promoting the subsistence and/or proliferation of neural stem cells is screened.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO2000006724A1 *29 Jul 199910 Feb 2000Kirin Beer Kabushiki KaishaRemedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
WO2001088100A1 *16 May 200122 Nov 2001Kyowa Hakko Kogyo Co., Ltd.Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
JP2002325571A * Title not available
JP2002371005A * Title not available
Non-Patent Citations
Reference
1HIRABAYASHI; KASAI J BIOL CHEM vol. 26, no. 8, pages 23648 - 23653
2HIRABAYASHI; KASAI J BIOL CHEM vol. 268, pages 23648 - 23653
3 *HORIE, H. ET AL.: 'Galectin-1 regulates initial axonal growth in peripheral nerves after axotomy' J.NEUROSCI. vol. 19, no. 22, 1999, pages 9964 - 9974, XP002983702
4 *HORIE, H. ET AL.: 'Identification of oxidized galectin-1 as an initial repair regulatory factor after axotomy in peripheral nerves' NEUROSCI.RES. vol. 38, no. 2, 2000, pages 131 - 137, XP001059710
5 *INAGAKI, Y. ET AL.: 'Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties' EUR.J.BIOCHEM. vol. 267, no. 10, 2000, pages 2955 - 2964, XP002983701
6See also references of EP1674566A1
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2007114473A1 *4 Apr 200711 Oct 2007Keio UniversitySignal transduction system activator
US7662385 *9 Feb 200716 Feb 2010Keio UniversityAgent for inhibiting proliferation of neural stem cells
US943993119 Aug 201313 Sep 2016Medipost Co., LtdAdministering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury
Classifications
International ClassificationA61P9/00, A61P25/00, A61K35/30, C12N5/0797
Cooperative ClassificationA61K35/30, C12N2501/59, C12N5/0623
European ClassificationC12N5/06B8P, A61K35/30
Legal Events
DateCodeEventDescription
24 Mar 2005AKDesignated states
Kind code of ref document: A1
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
24 Mar 2005ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG
18 May 2005121Ep: the epo has been informed by wipo that ep was designated in this application
8 Mar 2006WWEWipo information: entry into national phase
Ref document number: 2005513873
Country of ref document: JP
9 Mar 2006WWEWipo information: entry into national phase
Ref document number: 10571277
Country of ref document: US
Ref document number: 2007098701
Country of ref document: US
7 Apr 2006WWEWipo information: entry into national phase
Ref document number: 2004787726
Country of ref document: EP
28 Jun 2006WWPWipo information: published in national office
Ref document number: 2004787726
Country of ref document: EP
3 May 2007WWPWipo information: published in national office
Ref document number: 10571277
Country of ref document: US